Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 354

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 2
Chunk 354
---
 10.2 to the Current
    Report on Form 8-K filed November 20, 2023).
  
    4.3
     
    Representative’s
    Warrant, dated August 7, 2023 (incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K filed August
    7, 2023).
  
    4.4*
     
    Description of Securities of the Registrant
  
    10.1+
     
    2022
    Omnibus Incentive Plan, as amended and restated (incorporated by reference to Exhibit 10.1 to Form S-1 filed July 28, 2023).
  
    10.2+
     
    Form
    of Stock Option Award under 2022 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.2 to Form S-1 filed July 28, 2023).
  
    10.3
     
    Form
    of Indemnification Agreement (incorporated by reference to Exhibit 10.3 to Form S-1 filed July 28, 2023).
  
    10.4
     
    Confirmatory
    Patent Assignment and Royalty Agreement, dated November 1, 2021, between SRQ Patent Holdings II, LLC and MIRA Pharmaceuticals, Inc.
    (incorporated by reference to Exhibit 10.4 to Form S-1 filed July 28, 2023).
  
    10.5
     
    Amended
    and Restated Limited License Agreement, dated June 27, 2022, between MIRA Pharmaceuticals, Inc. and MyMD Pharmaceuticals, Inc. (incorporated
    by reference to Exhibit 10.5 to Form S-1 filed July 28, 2023).
  
    10.6
     
    Amendment
    No. 1, dated April 20, 2023, to Amended and Restated Limited License Agreement between MIRA Pharmaceuticals, Inc. and MyMD Pharmaceuticals,
    Inc. (incorporated by reference to Exhibit 10.6 to Form S-1 filed July 28, 2023).
  
    10.7+
     
    Employment Agreement, dated April 28, 2023, between MIRA Pharmaceuticals, Inc. and Erez Aminov (incorporated by